Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Clinical trial NCT05155033 · RECRUITING

Trial details

NCT number: NCT05155033
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma Advanced Locoregional Melanoma Metastatic Renal Cell Carcinoma Clear Cell Histology

Start date: 2022-08-18
Primary completion: 2031-09-01
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.